HealthcareServices

Short Bowel Syndrome Market Trends and Insights: Global Forecast to 2030

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the short bowel syndrome market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Short Bowel Syndrome Market covering 2026–2035?

The market size for short bowel syndrome has experienced rapid growth in recent years. It is projected to expand from $3.08 billion in 2025 to $3.53 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.6%. The market’s historic growth can be attributed to factors such as the increasing prevalence of short bowel syndrome, the historically limited treatment options available, a reliance on parenteral nutrition, a rise in gastrointestinal surgeries, and growing hospital awareness.

The market size for short bowel syndrome is projected to experience rapid expansion in the next few years, reaching $6.02 billion by 2030 at a compound annual growth rate (CAGR) of 14.2%. This growth over the forecast period is attributable to the development of novel therapeutics, increasing availability of home infusion services, personalized treatment approaches, the integration of microbiome therapies, and a rise in clinical trials for SBS interventions. Major trends expected during this period include an increase in parenteral nutrition solutions, the advancing development of intestinal rehabilitation therapies, the adoption of novel surgical interventions, a growing emphasis on gut microbiome modulation, and the expansion of patient support programs.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Short Bowel Syndrome Market?

The rising occurrence of gastrointestinal diseases is anticipated to drive the expansion of the short bowel syndrome market in the coming years. Gastrointestinal diseases refer to a broad category of conditions that affect the digestive tract, encompassing disorders of the stomach, intestines, liver, and pancreas, often leading to compromised digestion and nutrient absorption. The increasing incidence of these diseases is primarily fueled by unhealthy dietary habits that negatively impact gut health and promote inflammation. Such gastrointestinal conditions can contribute to the development of short bowel syndrome by necessitating the surgical removal of damaged intestinal segments, which results in a diminished absorptive capacity. For instance, in September 2023, data from the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canada-based organization dedicated to improving the lives of patients with Crohn’s disease and ulcerative colitis, revealed that in 2023, over 320,000 people in Canada suffered from inflammatory bowel disease (IBD), with a prevalence of 825 per 100,000. Given that the prevalence is projected to increase by 2.44% annually, it is estimated that 1.1% of the population, or 470,000 Canadians, will be living with IBD by 2035. Consequently, the increasing prevalence of gastrointestinal diseases is propelling the growth of the short bowel syndrome market.

What Segments Are Identified Within The Structure Of The Short Bowel Syndrome Market?

The short bowel syndrome market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide (GLP-2), Growth Hormone, Glutamine

2) By Diagnosis: Physical Exam, Blood Tests, Fecal Fat Tests, Imaging Procedures, Other Diagnosis

3) By Treatment: Nutritional Therapy, Medications, Surgery, Transplant

4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Other Distribution Channels

Subsegments:

1) By Glucagon-Like Peptide (GLP-2): Teduglutide, Other GLP-2 Analogues

2) By Growth Hormone: Somatropin, Other Growth Hormone Therapies

3) By Glutamine: Oral Glutamine, Intravenous Glutamine

Which Innovation Trends Are Advancing Developments Within The Short Bowel Syndrome Market?

Leading companies in the short bowel syndrome market are prioritizing the creation of innovative medical advancements, such as therapies for intestinal failure, to offer an advanced treatment option that improves patient outcomes for those with gastrointestinal disorders. Intestinal failure is a severe condition where the small intestine is unable to absorb sufficient nutrients, fluids, and electrolytes to maintain adequate hydration and nutrition. For instance, in May 2024, Ironwood Pharmaceuticals, Inc., a US-based healthcare company, released new data from studies evaluating apraglutide in adults with short bowel syndrome and intestinal failure (SBS-IF). As a next-generation GLP-2 analog, apraglutide exhibited potential to improve intestinal absorption and lessen the dependence on parenteral support. These findings emphasize the drug’s efficacy, safety, and long-term advantages, reflecting Ironwood’s dedication to developing novel treatments for gastrointestinal disorders.

Which Major Firms Are Strengthening Their Position In The Short Bowel Syndrome Market?

Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co Ltd, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc, OxThera Inc, EnteraBio Ltd, GLyPharma Therapeutic Inc, Fresenius Kabi AG, Danone S A, B Braun Melsungen AG, Medtronic plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Short Bowel Syndrome Market?

North America was the largest region in the short bowel syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Short Bowel Syndrome Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp

Browse Through More Reports Similar to the Global Short Bowel Syndrome Market 2026, By The Business Research Company

Ulcerative Colitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/ulcerative-colitis-global-market-report

Bowel Management Systems Market Report 2026

https://www.thebusinessresearchcompany.com/report/bowel-management-systems-global-market-report

Inflammatory Bowel Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795